Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Aim(s): To evaluate the antitumor effect of everolimus, an mTOR inhibitor, in preclinical models of PDNECs.
Materials and methods: The effect of everolimus on the activity of the mTOR pathway was assessed in two endocrine tumor cell lines: STC-1 and GluTag. Grafted to immunodeficient mice, these cells induce intrahepatic tumors representative of PDNECs by their morphological characteristics, their high proliferative activity and constitutive activation of the mTOR pathway.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
, Couderc C
, Blanc M
, Poncet G
, Lepinasse F
, Hervieu V
, Gouysse G
, Ferraro-Peyret C
, Benslama N
, Walter T
, Scoazec J Y
, Roche C
To read results and conclusion, please login ...
Further abstracts you may be interested in